ICD-10-CM Codes
R00-R99
R97-R97
R97-
2023 ICD-10-CM Diagnosis Code R97.21

2023 ICD-10-CM Diagnosis Code R97.21

Rising PSA following treatment for malignant neoplasm of prostate

2017 - New Code

2018

2019

2020

2021

2022

2023

Billable/Specific Code

Adult Dx (15-124 years)

Male Dx

Questionable As Admission Dx

R97.21 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Short description: Rising PSA fol treatment for malignant neoplasm of prostate
The 2023 edition of ICD-10-CM R97.21 became effective on October 1, 2022.
This is the American ICD-10-CM version of R97.21 - other international versions of ICD-10 R97.21 may differ.

ICD-10-CM Coding Rules

R97.21 is applicable to adult patients aged 15 - 124 years inclusive.
R97.21 is applicable to male patients.
R97.21 is not usually sufficient justification for admission to an acute care hospital when used a principal diagnosis.

The following code(s) above R97.21 contain annotation back-references

Annotation Back-References

In this context, annotation back-references refer to codes that contain:

Applicable To annotations, or
Code Also annotations, or
Code First annotations, or
Excludes1 annotations, or
Excludes2 annotations, or
Includes annotations, or
Note annotations, or
Use Additional annotations

that may be applicable to R97.21:

R00-R99
2023 ICD-10-CM Range R00-R99
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Note
- This chapter includes symptoms, signs, abnormal results of clinical or other investigative procedures, and ill-defined conditions regarding which no diagnosis classifiable elsewhere is recorded.
- Signs and symptoms that point rather definitely to a given diagnosis have been assigned to a category in other chapters of the classification. In general, categories in this chapter include the less well-defined conditions and symptoms that, without the necessary study of the case to establish a final diagnosis, point perhaps equally to two or more diseases or to two or more systems of the body. Practically all categories in the chapter could be designated 'not otherwise specified', 'unknown etiology' or 'transient'. The Alphabetical Index should be consulted to determine which symptoms and signs are to be allocated here and which to other chapters. The residual subcategories, numbered .8, are generally provided for other relevant symptoms that cannot be allocated elsewhere in the classification.
- The conditions and signs or symptoms included in categories R00-R94 consist of:
- (a) cases for which no more specific diagnosis can be made even after all the facts bearing on the case have been investigated;
- (b) signs or symptoms existing at the time of initial encounter that proved to be transient and whose causes could not be determined;
- (c) provisional diagnosis in a patient who failed to return for further investigation or care;
- (d) cases referred elsewhere for investigation or treatment before the diagnosis was made;
- (e) cases in which a more precise diagnosis was not available for any other reason;
- (f) certain symptoms, for which supplementary information is provided, that represent important problems in medical care in their own right.
Type 2 Excludes
- abnormal findings on antenatal screening of mother (O28.-)
- certain conditions originating in the perinatal period (P04-P96)
- signs and symptoms classified in the body system chapters
- signs and symptoms of breast (N63, N64.5)
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
R97
ICD-10-CM Diagnosis Code R97
Abnormal tumor markers
Applicable To
- Elevated tumor associated antigens [TAA]
- Elevated tumor specific antigens [TSA]
Abnormal tumor markers

ICD-10-CM R97.21 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):

947 Signs and symptoms with mcc
948 Signs and symptoms without mcc

Convert R97.21 to ICD-9-CM

Code History

2017 (effective 10/1/2016): New code
2018 (effective 10/1/2017): No change
2019 (effective 10/1/2018): No change
2020 (effective 10/1/2019): No change
2021 (effective 10/1/2020): No change
2022 (effective 10/1/2021): No change
2023 (effective 10/1/2022): No change

Code annotations containing back-references to R97.21:

Use Additional: C61

ICD-10-CM Diagnosis Code C61
Malignant neoplasm of prostate
Type 1 Excludes
- malignant neoplasm of seminal vesicle (C63.7)
Use Additional
- code, if applicable, to identify:
- hormone sensitivity status (Z19.1-Z19.2)
- rising PSA following treatment for malignant neoplasm of prostate (R97.21)

Diagnosis Index entries containing back-references to R97.21:

Rising, PSA following treatment for malignant neoplasm of prostate R97.21

ICD-10-CM Codes Adjacent To R97.21

R94.4 Abnormal results of kidney function studies

R94.5 Abnormal results of liver function studies

R94.6 Abnormal results of thyroid function studies

R94.7 Abnormal results of other endocrine function studies

R94.8 Abnormal results of function studies of other organs and systems

R97 Abnormal tumor markers

R97.0 Elevated carcinoembryonic antigen [CEA]

R97.1 Elevated cancer antigen 125 [CA 125]

R97.2 Elevated prostate specific antigen [PSA]

R97.20 Elevated prostate specific antigen [PSA]

R97.21 Rising PSA following treatment for malignant neoplasm of prostate

R97.8 Other abnormal tumor markers

R99 Ill-defined and unknown cause of mortality

S00 Superficial injury of head

S00.0 Superficial injury of scalp

S00.00 Unspecified superficial injury of scalp

S00.00XA …… initial encounter

S00.00XD …… subsequent encounter

S00.00XS …… sequela

S00.01 Abrasion of scalp

S00.01XA …… initial encounter

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

2023 ICD-10-CM Diagnosis Code R97.21

Rising PSA following treatment for malignant neoplasm of prostate

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Abnormal tumor markers

Malignant neoplasm of prostate